Ambu schedules November 5 annual report: Ambu stock gains 2.47 percent

Published on 10/20/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 organic growth reached 10.30 percent in fiscal 2025/26. Ambu stock costs EUR 10.28 on October 20, 2026 at Lang & Schwarz.

Reporting date November 5, 2026

Ambu published its annual report date of November 5, 2026, on September 30, 2026.
Ambu reported 10.30 percent organic growth and a 13.50 percent reported EBIT margin in the third quarter of fiscal 2025/26.
Ambu stock costs EUR 10.28 at Lang & Schwarz on October 20, 2026 at 8:43 p.m. CEST.
UBS cut its target from DKK 96.00 to DKK 72.00 on September 15, 2026.

Schwarzweiß-Reportage aus dem Operationssaal mit Endoskopie-Technik — Ambu A/S (DK0060946788) dokumentiert schwarzweiß eine dramatische Operationssaal-Szene mit Endoskopie-Ausrüstung im Krankenhaus, Illustration mit AI erstellt.

Ambu will publish its annual report for fiscal 2025/26 on November 5, 2026, according to MarketScreener, which carried the company announcement dated September 30, 2026. The report date gives investors the next fixed checkpoint after Ambu's third-quarter update. Ambu stock was at EUR 10.28 at Lang & Schwarz on October 20, 2026 at 8:43 p.m. CEST.

Growth remains led by endoscopy

Ambu delivered 10.30 percent organic growth in the third quarter of fiscal 2025/26, while Endoscopy Solutions grew 16.00 percent and represented 64.00 percent of revenue. The figures were discussed in the earnings call published by Yahoo Finance on August 26, 2026.

Respiratory growth reached 17.10 percent in the quarter, while Anesthesia and Patient Monitoring returned to positive growth of 1.60 percent. Reported EBIT margin was 13.50 percent, up from 11.30 percent in the comparable quarter, according to the transcript.

What does the target reset imply?

UBS cut its Ambu target from DKK 96.00 to DKK 72.00 and lowered its recommendation to Neutral on September 15, 2026, as reported by MarketScreener. A separate target overview from TargetWatch listed the same DKK 72.00 target and identified UBS as the latest named analyst firm.

Dates and valuation markers

Ambu's annual general meeting is scheduled for December 2, 2026, while the next quarterly earnings release is set for January 28, 2027. The company also expects to launch its newly cleared pediatric bronchoscopes across the United States and Europe in early 2027, according to Ambu.

For valuation context, MarketScreener listed a consensus of eight analysts, an average target of DKK 81.10 and a price-to-earnings ratio of 40.26. The Copenhagen share closed at DKK 76.90 on October 20, 2026, up 2.47 percent on the day.

Stock position after hours

Ambu's current euro quotation gives the stock a clear market reference ahead of the November report, while the DKK 72.00 UBS target remains below the latest Copenhagen close. The next scheduled corporate date is November 5, 2026.

Ambu was trading at EUR 10.28 at Lang & Schwarz on October 20, 2026 at 8:43 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Ambu stock.